← Back to DonatienInvestment Report archive →

NYSE:MRK Merck & Co., Inc.

ISIN: US58933Y1055
Health CarePharmaceuticalsLarge-Cap
NYSE · Rahway, NJ · Drug Manufacturers – General · mkt cap ~US$309bn Analysis Status: On-Going
All figures in US$ unless noted.
$125.07
-0.73%
10 Jul 2026 · Signal v6

Changes Since Last Report (vs. 16 Jun 2026)

Reactivated from ‘removed’. MRK was tracked, then removed; the Stock-Finder just re-rated it Watchlist, so this is a full fresh report and the Analysis Status flips removed → on-going. The signal is unchanged from the prior run — BUY across all three horizons — but the price has moved up and the scores firmed.

DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Merck & Co., Inc.

Merck & Co. (known as MSD outside the US and Canada) is one of the world's largest research-driven pharmaceutical companies, founded in 1891 and headquartered in Rahway, New Jersey. Its core business is discovering, developing and selling prescription medicines and vaccines across oncology, vaccines, cardiovascular, immunology, virology and neuroscience, plus a sizeable Animal Health division. Its defining asset is Keytruda, the world's best-selling cancer immunotherapy (roughly US$30bn a year, about 40% of pharmaceutical revenue), alongside the Gardasil HPV-vaccine franchise and newer growth drugs like Winrevair for pulmonary arterial hypertension. What sets Merck apart is the depth of its oncology science and a vaccine portfolio protected by scale, manufacturing complexity and patents — but the flip side is heavy dependence on a single blockbuster whose main US patents expire in 2028. For a reader, think of Merck as a cash-rich, dividend-paying pharma giant racing to build a pipeline big enough to replace its one dominant drug before the clock runs out.

HorizonSignalComposite ScoreConfidenceKey Driver
Short-term (1–3 mo)BUY6062%Uptrend intact, but near 52-wk-high resistance
Medium-term (6–12 mo)BUY6466%Cheap on clean earnings + defensive tailwind
Long-term (3–5 yr)BUY6670%Quality franchise, patent cliff the swing factor
Next update: 2026-07-24 — default +14d (Q2 earnings 2026-08-04 is beyond the 14-day window; the 14d refresh runs first)
Table of Contents
1Five-Pillar Scorecard2Hard Gates & Do-Not-Buy Status3Pillar Detail: Business Quality4Pillar Detail: Valuation Attractiveness5Pillar Detail: Underlying Drivers6Pillar Detail: Economic Alignment7Pillar Detail: Entry/Exit Timing8Economic Event Risk9Multi-Timeframe Technical Analysis10Price Chart (6-Month Daily)11Scenario Summary12Entry / Exit Rules13Position Sizing Context14Calibration Snapshot15Data Sources & Methodology
1

Five-Pillar Scorecard

Five independent scores — each 0–100 with its own confidence. The three fundamental pillars (Quality / Valuation / Timing) set the base BUY/HOLD/SELL via the Decision Matrix; the two context pillars (Underlying Drivers, Economic Alignment) then amplify a BUY to STRONG BUY or a SELL to STRONG SELL when both corroborate.

Business Quality

68
strong
conf 72%

Valuation Attractiveness

68
attractive
conf 78%

Entry/Exit Timing

58
constructive
conf 62%

Underlying Drivers

55
Neutral
conf 60%

Economic Alignment

64
Trend-Following
conf 66%
2

Hard Gates & Do-Not-Buy Status

Binary safety checks — any TRIGGERED gate is a hard cap regardless of the scores above; CAUTION gates are sizing notes.
✅
Financial Distress
Net debt/EBITDA ~1.6× on clean operating EBITDA; interest coverage 17×; current ratio 1.30. No distress.
✅
Earnings Event (14d)
Q2 earnings 2026-08-04 is 25 days out — outside the 14-day blackout, so no timing cap.
✅
Valuation Ceiling
Clean fwd P/E ~13.9× vs a warranted ~18.1× (ratio 0.77) and well below the 22× Health-Care guardrail. Not expensive.
⚠️
Accounting / Dilution
Reported TTM P/E (35×) and negative TTM EBITDA are distorted by the ~$9bn Q1 acquired-IPR&D charge (Cidara/Verona/Terns) — a one-off, fully disclosed. Scored on clean/operating earnings per step 7b. Share count flat/falling; no dilution.
✅
Regulatory / Binary Event
Diversified $309bn pharma; no single dated readout would move the stock >20%. Subcutaneous Keytruda (QLEX) is already approved. Keytruda IRA price-setting (effective 2028–29) and the 2028 US LOE are known, phased, not binary — handled as the driver/bear case, not a gate.
✅
Severe Driver Collapse
Driver score 55 — nowhere near the ≤15 collapse floor.
Net gate read: CLEAR, one caution. The only flag is an accounting caution — reported net income, P/E, EBITDA and payout ratio are all distorted downward by a one-off ~$9bn Q1 acquired-in-process-R&D charge. This report scores Quality and Valuation on clean/operating earnings (step 7b), so the distortion does not flatter the signal. No hard gate is triggered and no Do-Not-Buy trigger fires.
3

Pillar Detail: Business Quality

A deep dive into the Quality score: business economics, moat, ROIC and the industry benchmark.
Business Quality — Pillar Score
A top-tier oncology and vaccines franchise with elite margins and cash generation — capped, not sunk, by single-drug concentration and a 2028 patent cliff.
68
conf 72%

Lifecycle & sector: Mature large-cap pharma (Healthcare / Pharma — Mature). Revenue growth is mid-single-digit (Q1'26 +5% YoY to $16.29bn), the company is highly profitable and cash-generative, and capital returns (2.7% dividend) matter — the textbook mature-pharma profile. Metrics used: R&D efficiency, patent-cliff exposure, operating margin, ROIC, moat — not growth-stage or pre-revenue lenses.

Earnings-quality note (see §4 for the full decomposition): Q1'26 reported a GAAP loss (–$1.72 EPS) purely because of a one-off ~$9bn acquired-IPR&D charge from the Cidara/Verona/Terns deals. Stripping it out, the underlying business earns a clean run-rate of roughly $9 of EPS on ~41% clean operating margin. All Quality sub-scores below are read on the clean operating business, not the charge-distorted headline.

Sub-signalValuePeer / historyScoreRead
Revenue trajectory+5% YoY (Q1'26)Mature-pharma median ~3–5%62In-line for the sector; Keytruda +12%, Winrevair +88%, Gardasil soft.
Clean operating margin~41%Big-pharma 30–40%80Top-tier once the one-off charge is removed.
Cash generationFCF/sh $5.71; ~$14bn TTM FCFStrong, covers the dividend ~1.5× with capex72Reliable cash machine; payout looks stretched only on the charge-distorted number.
Balance sheetNet debt/clean-EBITDA ~1.6×; int cover 17×D/E 1.07, current 1.3070Comfortable; ample capacity to keep bolting on pipeline.
R&D efficiency & pipeline~$70bn+ of stated post-Keytruda opportunity; 20+ potential launchesDeep but unproven vs the cliff60The whole thesis — can the pipeline replace Keytruda in time?
Industry Benchmark — R&D Efficiency + Patent Cliff: 55/100. R&D productivity is genuinely strong (Keytruda, Gardasil, Winrevair, subcutaneous QLEX, an active oncology/cardio pipeline). But patent-cliff exposure is the opposite of healthy: Keytruda is ~40% of pharmaceutical revenue with US loss-of-exclusivity in 2028 plus IRA price-setting phasing in 2028–29 — well past the >30%-single-drug red-flag line. Strong pipeline, high cliff = Mixed. This is the single biggest drag on Quality.
Pricing power
62
Patent-protected oncology/vaccines command price, but US drug-pricing policy (IRA negotiation) is now a live cap on Keytruda.
Network effects
50
N/A for pharma — scored neutral.
Switching costs
55
Physician familiarity and standard-of-care inertia help, but a superior rival regimen can displace — trimmed for the live PD-1×VEGF next-gen threat (see Competitive Environment).
Cost advantage
68
Scale in manufacturing (esp. vaccines/biologics) and global commercial reach are hard to replicate.
Intangible assets
78
Deep patent estate, oncology brand leadership, Gardasil franchise, regulatory know-how — the real moat, but a decaying one on the flagship as 2028 nears.

Moat average: ~63. A wide moat today, narrowing on the flagship as the Keytruda cliff approaches — which is exactly why the pipeline race sets the whole thesis.

Competitive Environment — threat level: ELEVATED (share trajectory: stable now, structurally losing on Keytruda post-2028). Merck's moat is measured today; here is who is attacking it and which way share trends.
RivalThreat typeShare trajectoryMoat-erosion vector
Bristol Myers Squibb (Opdivo/Opdualag)Direct PD-1 rivalMerck stable/leadingKeeps Keytruda pricing honest; both face their own cliffs.
Ivonescimab (Summit Therapeutics / Akeso)Next-gen PD-1×VEGF bispecificMerck at risk post-2027The credible technology-parity threat — head-to-head data suggesting a bispecific could displace PD-1 monotherapy in key lung-cancer settings, straight into the LOE window.
Keytruda biosimilarsLow-cost entrantsMerck losing (from 2028)The mechanical cliff — US LOE 2028 opens biosimilar entry; subcutaneous QLEX and IRA price-setting shape how steep the erosion is.
AstraZeneca / Eli Lilly / PfizerOncology & adjacency rivalsMixedBroad oncology competition; LLY's GLP-1 dominance is an adjacent share-of-pharma-wallet pressure, not a direct Keytruda threat.
→ Net effect on the moat: Switching Costs trimmed to 55 and Pricing Power to 62 to reflect the ivonescimab parity threat and IRA pricing; the mechanical 2028 biosimilar cliff is carried in the §11 Bear trigger and the §12 thesis-invalidation, not in today's moat number.
ROIC & Capital Allocation: ~70. High ROIC on the clean operating base (FMP ROE sub-score 5/5, ROA 4/5). Capital allocation is disciplined-aggressive: three bolt-on deals in ~10 months (Cidara, Verona/Ohtuvayre, Terns) to backfill the cliff, funded from strong FCF while sustaining a 2.7% dividend. Execution risk on integration is the watch-item, but the framework and the balance-sheet capacity are sound.
4

Pillar Detail: Valuation Attractiveness

Sector-appropriate multiples, FCF yield, reverse-DCF implied growth, embedded optionality, and the analyst-consensus cross-check.
Valuation Attractiveness — Pillar Score
Cheap against its own rate-and-growth-warranted multiple once the one-off charge is stripped out — Attractive band, with real cliff risk already partly in the price.
68
conf 78%
Earnings-quality decomposition (step 7b) — normalise UP, not down. The usual trap is a gain inflating earnings; here it is the opposite. Q1'26 R&D expense was $12.56bn (vs a ~$3.5bn run-rate) because Merck booked ~$9bn of one-off acquired-in-process-R&D charges on the Cidara, Verona and Terns deals — fully disclosed, non-recurring, non-operating in substance. That single charge dragged Q1 to a –$4.24bn net loss and pushed reported TTM net income to ~$8.9bn, TTM EPS ~$3.61, reported P/E ~35×, TTM EBITDA negative, payout ratio ~92% — none of which reflect the ongoing business. Clean run-rate EPS is ~$9.0 (2027 consensus EPS $9.64 corroborates it). Every multiple below is scored on the clean number. nonop_pct_of_net_income ≈ 100%+ of the swing; clean_pe ≈ 13.9×; clean_peg ≈ 2.3.
THE ANCHOR — Warranted-Multiple Valuation. A high-quality pharma's fair P/E is set by rates and disciplined growth, not by peers. r = 4.56% (10-Y Treasury, DGS10 as of 2026-07-08) + 4.5% ERP + 0.0% (Quality ≥ 65) = 9.06%. g_near = min(0.75 × ~6% consensus, 10% Health-Care cap) = ~4.5%; g_term = 3%. Two-stage warranted P/E ≈ 18.1× (below the 22× Health-Care guardrail, so no cap binds; 10-Y is under 5% so no tightening).
Score = actual ÷ warranted = 13.9× ÷ 18.1× = 0.77 → Attractive band. Clean multiple sits comfortably below both the warranted line and the industry guardrail — the intrinsic anchor says Merck is cheap for what the business earns, even after haircutting growth. Implied-growth read: at $125 on clean $9 EPS, the market is pricing roughly flat-to-low-single-digit long-run growth — i.e. it is already discounting a meaningful post-2028 Keytruda step-down. Our disciplined estimate (~4.5% near-term) is modestly above what the price embeds, which is the source of the Attractive read.
MultipleCurrent (clean)Sector medianOwn 5-yr decileRead
Forward P/E (clean)~13.9×Big-pharma ~15–16×Low (3rd)Below sector and near the low end of its own range.
EV/EBITDA (clean)~10–11×~11–12×Low–midReasonable; reported EV/EBITDA is meaningless (charge).
FCF yield~4.6% (clean ~6%)3–5% quality-pharmaAttractiveSolid cash yield backing a covered dividend.
Dividend yield2.7%——Income cushion while the cliff plays out.
Embedded Optionality / Free Upside. The core in-production business (Keytruda, Gardasil, Winrevair, Animal Health) justifies most of the ~$125 price. On top, the buyer gets several under-priced options for ~free: (1) the subcutaneous Keytruda (QLEX) life-cycle extension — $128m in Q1, could soften the biosimilar cliff more than consensus models; (2) the pipeline backfill from three 2026 bolt-ons (Cidara antiviral, Verona/Ohtuvayre in respiratory, Terns oncology) that the market is largely valuing at deal cost, not success-case; (3) Winrevair label/indication expansion (already +88% YoY); (4) the Moderna personalised-cancer-vaccine collaboration. Each is "unquantified but real." Net: this is a +5 tilt to Valuation — the price is Attractive on the core and you own the cliff-mitigation options for little.
Analyst consensus: price-target consensus $135.33 (median $140.5, high $155, low $100) → ~8% upside to consensus, ~12% to median; recent (last-month) targets average $148.67, skewing higher. Coverage deep (68 all-time, 24 last-year). Grades: 25 Buy / 11 Hold / 1 Sell / 0 Strong-Sell → Buy consensus, ~68% bullish. FMP health rating B (3/5) — dragged only by the P/E (2) and P/B (1) sub-scores, both computed on the charge-distorted reported figures; ROE (5) and ROA (4) confirm the underlying quality. The FMP P/E flag is a data artefact of the one-off charge, not a valuation concern.
5

Pillar Detail: Underlying Drivers

The dominant external force the stock is tethered to, scored 0–100. A context pillar: it does not change the base signal — it feeds amplification (tailwind ≥65 can lift BUY→STRONG BUY; headwind ≤35 can push SELL→STRONG SELL).
Primary Driver
Pipeline build-out vs. Keytruda patent cliff (2028 LOE + IRA)
55
Neutral — no amplification

The dominant force over Merck is not the macro economy — it is the race between its pipeline and its own flagship's patent cliff. Keytruda (~$30bn/yr, ~40% of pharmaceutical revenue) loses US exclusivity in 2028, and it was selected for Medicare IRA price-setting with negotiated prices effective 2028–29. That is a large, dated, known step-down. Against it Merck is building: subcutaneous Keytruda (QLEX) to retain patients, Winrevair (+88% YoY, PAH), a broad oncology/cardio pipeline, and three 2026 bolt-on acquisitions. The driver is the balance of these two forces — and today it nets to Neutral.

HorizonReadBasis
Historical (12–24m)ImprovingWinrevair scaled to blockbuster; QLEX approved; pipeline deepened via M&A; stock +23% YTD as the market warmed to the backfill story.
CurrentNeutral / balancedKeytruda still growing (+12% Q1), pipeline momentum real — but the 2028 cliff and IRA pricing are firmly in view and un-resolved. Neither tailwind nor headwind dominates now.
Forward (6–12m)Neutral, event-drivenPipeline readouts and further bolt-ons could tilt it positive; a competitive/data setback (e.g. ivonescimab) or a harsher IRA outcome tilts it negative. Genuinely two-sided.

Driver score 55 → Neutral (36–64 band). This is not eligible to amplify: it is neither a ≥65 tailwind nor a ≤35 headwind, so the base BUY/HOLD/SELL from the fundamental pillars stands unchanged at every horizon. Thesis-invalidation floor: if Keytruda biosimilar/competitive erosion from 2028 outpaces the pipeline + QLEX backfill — i.e. total revenue is set to decline through 2028–29 with no offsetting launch — the driver flips to a Headwind and the whole case breaks. Driver confidence 60% (indirect, event-dependent, multi-year).

6

Pillar Detail: Economic Alignment

How the current economic climate sits relative to this stock, read from the latest Macro-Economic report. Classifies the macro pressure (Tailwind / Neutral / Headwind) — the second amplification input — and frames a long entry as Trend-Following or Contrarian with a 0–100 conviction.
Stance · Pressure
Trend-Following · Tailwind
64
conviction

The latest Macro-Economic report (2026-07-09) reads the regime as 'Higher-for-Longer / Stagflation-lite' and scores Health Care (XLV) N / O / O — Neutral short, Outperform medium and long — with real-money capital rotating into defensives (XLV flagged 'in' medium/long). In a higher-for-longer, decelerating-growth tape, rate-insensitive, cash-generative defensive pharma is exactly what the economy favours: Merck's beta is 0.205 and its cash flows are largely macro-insulated. That makes a long position Trend-Following (riding an economic tailwind), conviction 64. The pressure is a Tailwind — but because the Underlying Driver (55) is only Neutral, the amplification layer does NOT fire: the base BUY is not lifted to STRONG BUY at any horizon (STRONG BUY needs both Tailwind pressure AND driver ≥65). Short-horizon XLV is only Neutral, consistent with the constructive-but-extended timing read.

Source: watchlist sector-map (Health Care / XLV) · Macro report 2026-07-09

7

Pillar Detail: Entry/Exit Timing

The risk-reward framework, relative strength vs SPY and the sector ETF, the macro overlay, news-derived sentiment, and the catalyst cluster.
Entry/Exit Timing — Pillar Score
A clean, multi-timeframe uptrend and strong relative strength — tempered by price sitting just under 52-week-high resistance with hourly momentum fading.
58
conf 62%

Risk-reward: Price $125.07 sits ~4% below the 52-week high ($130.29) and well above the rising SMA50 ($117.95) and SMA200 ($108.14). The nearest logical stop is under the SMA50 / the $110–112 support shelf, ~11% away (~3× ATR of $3.48) — a fairly wide stop, so the risk-reward from here is only moderate; a pullback toward $118–120 would tighten it materially.

Relative strength: Strong. MRK is +23% YTD and up ~63% off its 52-week low ($76.66), outperforming a defensive-led tape and a top holding across SCHD/HDV/XPH dividend and pharma ETFs. Momentum leadership is a genuine positive for the medium horizon.

Macro overlay (Health-Care = LOW macro sensitivity, weight 0.10): Fed on hold/hawkish is broadly neutral for rate-insensitive pharma; the defensive rotation is a mild tailwind. VIX moderate. Net neutral-to-slightly-favourable.

Sentiment (analyst grades + news): All 12 most-recent grade actions are maintains (Overweight/Outperform/Buy heavy, a few Neutral/Equal-Weight) — no downgrades, no upgrades in 30 days → stable, mildly positive. News tone slightly positive (Keytruda +12%, Terns oncology deal, top dividend-ETF holding), balanced by 'merger-mania / patent-cliff' framing that keeps the 2028 risk salient.

TimeframeTrendRSIMACDKey S/RRead
MonthlyUptrend ↑62+ risingS 99 / R 134Secular uptrend, resistance breakout.
WeeklyUptrend ↑59+ flatS 96 / R 125Testing weekly resistance ~125.
DailyStrong uptrend ↑55+ smallS 112 / R 130Above all MAs; healthy, not overbought.
HourlyWeakening →46– flatS 124 / R 128Short-term consolidation/pullback under resistance.
15-minRecovering53flatS 124 / R 125Noise.

Confluence: Bullish (MTF ~68). Higher timeframes are firmly bullish; the only soft spot is intraday, right under the $130 high — a classic "strong trend pausing at resistance." The setup favours buying a pullback into $118–122 over chasing into the $130 ceiling. Timing 58 = constructive but not a fresh-breakout green light. Confidence 62% (no imminent earnings, but price is extended vs the ideal entry zone).

8

Economic Event Risk

High-impact macro releases in the next 14 days that could swing this stock, plus the last 7 days of surprises.

Upcoming events (next 30 days)

DateEventImpactForecastPreviousRelevant?Why
2026-07-14Core CPI YoY (Jun)Medium2.9%2.9%⚠️ LowHealth Care low macro-sensitivity; a hot print pressures rate-sensitive sectors, not defensive pharma. Indirect only.
2026-07-16Retail Sales (Jun)Medium+0.3%—NoConsumer-spending signal — not material to prescription pharma demand.
2026-08-04Merck Q2 2026 earnings (pre-mkt)High——✅ YesThe key ticker-specific event: Keytruda/QLEX trajectory, Winrevair, guidance, pipeline update. Sets the next real re-rating.

Recent surprises (last 7 days)

DateEventActualForecastSurpriseImpact
2026-07-09Initial Jobless Claims215K218Kbelow (tighter)Neutral for pharma
2026-07-08FOMC Minutes———Higher-for-longer tone — supports the defensive rotation Merck sits in
2026-07-0810-Y Note Auction4.58%——10-Y at 4.55–4.56% is the risk-free used in the valuation anchor

Merck carries LOW macro sensitivity — no economic release in the next 14 days is a first-order driver. The one event that matters is the company's own Q2 report on 4 Aug, which is beyond this refresh window; the 14-day cadence refresh (24 Jul) runs first and will pick up the earnings once it enters the window. No high-impact macro release inside a 3-day window, so no WAIT-for-event override.

9

Multi-Timeframe Technical Analysis

Trend, RSI and breakout status across monthly / weekly / daily / hourly / 15-minute, with a confluence verdict.
TimeframeTrendDirectionRSIMACDKey S/RBreakoutVol
MonthlyUptrendBullish62+, risingS 99 / R 134Resistance breakout0.2x
WeeklyUptrendBullish59+, flatS 96 / R 125Resistance breakout0.7x
DailyStrong UptrendBullish55+, smallS 112 / R 130Resistance breakout0.6x
HourlyWeakeningNeutral-Bearish46-, flatS 124 / R 128Support breakdownn/a
15-minRecoveringNeutral53flatS 124 / R 125Minor breakout0.2x
Confluence: Bullish · MTF Score 68

Monthly, weekly and daily are all in confirmed uptrends above their moving-average stacks — a strongly-bullish higher-timeframe picture. The only weakness is intraday: hourly has rolled over just beneath the $130 52-week-high resistance, a normal pause after a sharp June run from ~$115 to ~$130. Textbook read: buy the pullback into the $118–122 zone (rising SMA20/SMA50 region) rather than chase into resistance. Key level to watch: a decisive break and hold above $130 opens the $134 monthly resistance; failure there sends it back to test $118–120.

10

Price Chart (6-Month Daily)

A 6-month daily close line with SMA50 and key support/resistance — the visual companion to the MTF table.

MRK 6-month daily. A firm uptrend off the ~$107 January base to a ~$130 late-June high, now consolidating just below the 52-week high. Rising SMA50 ($118) and SMA200 ($108) sit beneath as support; $130 is the ceiling to clear.

11

Scenario Summary

Bull / Base / Bear 12-month price paths with triggers and probability weights.

Bull $155 (25%)

Keytruda holds share into 2028 with subcutaneous QLEX retaining a big slice of patients; the 2026 bolt-ons (Terns oncology, Verona respiratory, Cidara) and Winrevair deliver visible launches; IRA impact lands at the softer end. The clean-earnings base re-rates toward the sector on a de-risked cliff. Aligns with recent-month analyst targets clustering near $148 and the $155 high. Defensive rotation keeps a bid under it.

Base $138 (55%)

The most probable path: Merck compounds mid-single-digit revenue into 2027, the market keeps pricing a real but manageable 2028 step-down, and the stock drifts toward the ~$135–140 consensus/median as clean earnings (~$9 EPS) and the 2.7% dividend do the work. No cliff resolution yet, but no disaster — a ~10% total-return path from $125 including the dividend. This is the probability-weighted centre of gravity.

Bear $98 (20%)

The patent-cliff case turns real ahead of schedule: a competitive/data setback (e.g. ivonescimab displacing PD-1 monotherapy in key lung settings), a harsher-than-expected IRA price cut, and/or pipeline readouts that disappoint — so the Street starts modelling 2028–29 revenue decline with no offsetting launch. Keytruda biosimilar erosion + IRA compresses the multiple back toward its lows (~$98–100, the analyst-low anchor). This is the explicit Keytruda-cliff bear and the reason the position is BUY, not STRONG BUY.

Probability-weighted fair value ≈ $135 (0.25×$155 + 0.55×$138 + 0.20×$98), essentially in line with the $135.33 analyst consensus — ~8% above the current $125.07 before the 2.7% dividend. The distribution is asymmetric-but-fat-tailed on the downside because the 2028 cliff is a real, dated event; that fat left tail is exactly why the driver is Neutral and the signal is BUY rather than STRONG BUY.

12

Entry / Exit Rules

Three independent entry paths (Fundamental · Technical · Catalyst) and three exit triggers (Stop-Loss · Thesis · Profit-Target). Any one entry path is a valid entry — the more that agree, the larger the position the conviction ladder suggests. Exits are graded by severity, not count.

How to read this — the Conviction Ladder

The three entry groups are alternative paths to a buy, not a checklist. A group counts only when all its sub-conditions hold. How many groups are satisfied sets the suggested size — it does not gate whether you may enter: 1 group = Half-Size (a valid starter/scale-in), 2 = Full-Size, 3 = Over-Size (highest conviction); 0 = Wait (no path open yet). A strong overall signal can still read Wait here when the stock is well above its entry zones — that flags "good business, no entry edge right now," not a contradiction. Exits are graded by severity of what is live, not by a count: a hard stop is an Exit on its own.
Entry conviction: Half-Size1 of 3 groups met — one path open — starter / scale-in

Fundamental — MET

Trades below fair value on clean earnings, no earnings inside 7 days, driver not a headwind.
✅ Price $125.07 < fair value ~$135 (warranted + consensus)
✅ No earnings within 7 days (Q2 is 2026-08-04, 25 days out)
✅ Underlying-Driver score ≥ 50 (55, Neutral)

Technical — not MET

Uptrend intact but price is under 52-wk-high resistance; preferred entry is a pullback to the rising SMA50, not a chase.
⛔ Daily close > SMA50 ($118) — already true, but ideal add is a pullback INTO $118–122 with a higher low
✅ RSI 35–65 (daily 55)
⛔ MACD histogram positive ≥2 days OR turning up off support (daily + but hourly rolling over)

Catalyst — not MET

No confirming event in the window — next catalyst is the 4 Aug Q2 print.
· Post-earnings move >+5% with guidance raised/maintained
⛔ Volume > 2× the 20-day average

Forecast: Fundamental group is MET now (1 of 3 → Half-Size). The Technical group turns on a pullback into the $118–122 SMA50 zone with a higher low — forecast ~1–3 weeks if the $130 resistance rejects (the hourly is already softening), Moderate confidence; a clean break-and-hold above $130 would instead satisfy it via breakout (also Moderate, needs >1.5× volume). The Catalyst group is date-locked to Q2 earnings on 4 Aug — catalyst-dependent, unmet until then. A second group agreeing would lift sizing to Full.

Exit action: Holdno exit trigger is live — hold the position

Stop-Loss — not LIVE

⛔ Two daily closes below $110 (under the SMA50 / $111 support shelf)

Thesis Invalidation — not LIVE

⛔ Full-year guidance cut, OR revenue set to decline through 2028–29 as Keytruda biosimilar/competitive erosion outpaces the pipeline + QLEX backfill
⛔ Competitive invalidation: a named rival (ivonescimab / Keytruda biosimilars) demonstrably takes share such that Keytruda-franchise revenue rolls over faster than modelled
⛔ Underlying Driver flips to a Headwind (≤35)

Profit-Target — not LIVE

⛔ Price into $138–140 (base/median target) AND daily RSI > 70 AND no clean-earnings upgrade to justify the higher multiple

Forecast: No exit trigger is live — action is HOLD/accumulate. The $110 stop is ~12% below spot and below the rising SMA50, unlikely in 4–6 weeks absent a broad selloff or a bad 4 Aug print. The Profit-Target trim zone ($138–140) is ~11% up — reachable on a good quarter; watch RSI there. The thesis-invalidation legs are multi-quarter, cliff-driven watch-items, not near-term.

Imagine you act at the current price of $125.07 · as of 10 Jul 2026

What if you bought now?

You're risking ~12% (to the $110 stop) / ~22% (bear $98) to gain ~10% to base ($138) and ~24% to bull ($155) — plus a 2.7% dividend while you wait.

What you're risking: buying here means buying into a strong trend at its $130 resistance ceiling, above the ideal $118–122 entry zone — the Technical entry group is NOT yet met, so a starter (Half-Size) is the honest size. The hard stop is ~12% down at $110; the patent-cliff bear takes you to ~$98 (–22%). The 4 Aug Q2 print is path-risk you'd be holding through.

What you're gaining: immediate exposure to a franchise trading at ~0.77× its warranted multiple (Attractive), ~8% upside to the $135 consensus / probability-weighted fair value and ~24% to the bull, the 2.7% covered dividend compounding, and the pipeline/QLEX optionality for ~free. Risk-reward to base is ~0.8:1 from here, improving to ~1.5:1 on a pullback into $120. Read: a fair place to start a position; waiting for a dip toward the SMA50 (or the 4 Aug print) materially improves the entry — no need to chase the $130 ceiling.

What if you sold now?

You're giving up ~8% base / ~24% bull upside plus a 2.7% dividend to protect against a ~22% patent-cliff bear.

What you're giving up: selling (or staying out) at $125 forfeits the run to the ~$135–138 base and the optionality on a de-risked cliff — and you'd be selling a name the anchor calls below fair value.

What you're protecting: capital against the fat left tail — the 2028 Keytruda LOE + IRA is a real, dated risk that could drag the stock to ~$98. But no exit rule is live right now: no stop hit, no thesis break, price is below the profit-trim zone. Read: there is no mechanical reason to sell today — this is a hold/accumulate zone, not an exit.

13

Position Sizing Context

Illustrative portfolio math (not advice) translating conviction into an allocation given risk-per-share and volatility.

Position sizing not computed — no risk budget or portfolio role was specified for this run. The §12 Conviction Ladder reads Half-Size (1 of 3 entry groups met): the Fundamental path is open (cheap on clean earnings) but the Technical and Catalyst paths are not, so a starter/scale-in position is the framework-consistent size, with room to add on a pullback into $118–122 or a confirming 4 Aug print. ATR context: daily ATR ~$3.48 (~2.8% of price) — moderate volatility; the ~12% stop distance to $110 is wide, which itself argues for a smaller starting clip and adding lower.

14

Calibration Snapshot

Machine-readable snapshot of every score, level and signal, saved alongside the HTML so the next run can compute deltas.
{
  "ticker": "MRK",
  "exchange_ticker": "NYSE:MRK",
  "isin": "US58933Y1055",
  "country_table": "US",
  "date": "2026-07-10",
  "version": "v6",
  "prior_report": "MRK_Signal_v6_20260616_1703.html",
  "analysis_status": "on-going",
  "reactivation_note": "Reactivated from 'removed' \u2014 finder re-rated MRK Watchlist on the latest run.",
  "finder_ticker": "MRK",
  "finder_exchange": "\ud83c\uddfa\ud83c\uddf8 NYSE",
  "section": "Defensive Health Care",
  "user_context": {
    "horizon": "all",
    "allocation_pct": null,
    "portfolio_role": null
  },
  "sector": "Healthcare / Pharma (Mature)",
  "lifecycle_stage": "mature",
  "currency": "USD",
  "company": "Merck & Co., Inc.",
  "price_at_rating": 125.07,
  "signal_short": "BUY",
  "signal_medium": "BUY",
  "signal_long": "BUY",
  "primary_signal": "BUY",
  "quality_score": 68,
  "valuation_score": 68,
  "timing_score": 58,
  "driver_score": 55,
  "driver_label": "Neutral",
  "driver_name": "Pipeline build-out vs. Keytruda patent cliff (2028 LOE + IRA)",
  "economic_alignment_stance": "Trend-Following",
  "economic_alignment_conviction": 64,
  "economic_alignment_pressure": "Tailwind",
  "economic_alignment_source": "sector-map",
  "macro_report_date": "2026-07-09",
  "amplification_fired": false,
  "quality_detail": {
    "industry_benchmark_name": "R&D Efficiency + Patent Cliff",
    "industry_benchmark_value": "Keytruda ~40% of pharma revenue, US LOE 2028",
    "industry_benchmark_score": 55,
    "moat_score": 63,
    "roic_capital_score": 70,
    "keytruda_q1_2026_sales_usd_b": 8.0,
    "keytruda_qlex_q1_2026_sales_usd_m": 128,
    "winrevair_q1_2026_sales_usd_m": 525
  },
  "valuation_detail": {
    "clean_fwd_pe": 13.9,
    "reported_ttm_pe": 35.1,
    "clean_eps_runrate": 9.0,
    "fcf_yield_reported": 4.6,
    "fcf_yield_clean": 6.0,
    "dividend_yield": 2.7,
    "consensus_growth_rate": 6.0,
    "historical_valuation_decile": 3,
    "cidara_verona_terns_iprd_charge_usd_b": 9
  },
  "warranted_multiple": 18.1,
  "actual_multiple": 13.9,
  "val_multiple_basis": "clean forward P/E",
  "discount_rate_r": 9.06,
  "risk_free_10y": 4.56,
  "g_near": 4.5,
  "g_term": 3.0,
  "warranted_ratio": 0.77,
  "val_band": "attractive",
  "nonop_pct_of_net_income": 100,
  "clean_pe": 13.9,
  "clean_peg": 2.3,
  "competitive_share_trajectory": "stable",
  "competitive_threat_level": "elevated",
  "timing_detail": {
    "mtf_confluence": 68,
    "risk_reward_score": 52,
    "relative_strength": "strong (+23% YTD, +63% off 52wk low)",
    "catalyst_clustering_score": 70,
    "dynamic_macro_weight": 0.1
  },
  "analyst_consensus_target": 135.33,
  "analyst_target_high": 155,
  "analyst_target_low": 100,
  "analyst_target_median": 140.5,
  "analyst_target_upside_pct": 8.2,
  "analyst_grades_consensus": "Buy",
  "analyst_bullish_pct": 67.6,
  "analyst_coverage_count": 37,
  "recent_upgrades_30d": 0,
  "recent_downgrades_30d": 0,
  "fmp_rating": "B",
  "fmp_overall_score": 3,
  "overall_confidence": 62,
  "confidence_short": 62,
  "confidence_medium": 66,
  "confidence_long": 70,
  "fair_value_est": 135,
  "stop_loss": 110,
  "target_price": 138,
  "scenario_bull": 155,
  "scenario_base": 138,
  "scenario_bear": 98,
  "scenario_bull_target": 155,
  "scenario_base_target": 138,
  "scenario_bear_target": 98,
  "hard_gate_state": "caution",
  "gates_triggered": [],
  "gates_caution": [
    "accounting_iprd_charge_distortion",
    "keytruda_concentration_patent_cliff",
    "drug_pricing_ira"
  ],
  "do_not_buy_triggers": [],
  "gates_callout": "clear with accounting caution (one-off IPR&D charge normalised)",
  "entry_groups_met": 1,
  "entry_criteria_met": 1,
  "entry_criteria_total": 3,
  "entry_conviction": "Half-Size",
  "exit_groups_live": 0,
  "exit_criteria_met": 0,
  "exit_criteria_total": 3,
  "exit_action": "Hold",
  "thesis_invalidation_floor": "Keytruda biosimilar/competitive (ivonescimab) erosion from 2028 outpaces the pipeline + subcutaneous-QLEX backfill so that total revenue is set to decline through 2028-29, and/or a full-year guidance cut or harsher-than-expected IRA outcome \u2014 driver flips to Headwind and the case breaks.",
  "next_update_date": "2026-07-24",
  "next_check_date": "2026-07-24",
  "next_update_basis": "default +14d (Q2 earnings 2026-08-04 is beyond the 14-day window; the 14d refresh runs first and re-schedules once earnings enters the window)",
  "report_filename": "MRK_Signal_v6_20260710_0626.html"
}
15

Data Sources & Methodology

Audit trail of every data source: fully available (✓), fallback (⚠), or failed (✗), plus provenance-based confidence haircuts.
Data Source Status
✓
get_company_profile Sector, mkt cap $309bn, beta 0.205, ISIN US58933Y1055, description.
✓
get_stock_snapshot / get_stock_prices Prev close $125.07; 123 daily bars for the 6-mo chart + technicals.
✓
get_income_statement (6q) Q2'25–Q1'26; surfaced the ~$9bn Q1 acquired-IPR&D charge that drove the earnings-quality normalisation.
✓
get_financial_ratios TTM margins, coverage, FCF/sh, dividend — reported P/E flagged as charge-distorted.
✓
get_multi_timeframe_analysis 5-timeframe trend/RSI/MACD/S-R; confluence strongly bullish.
✓
get_price_target_consensus / _summary Consensus $135.33, median $140.5, high $155, low $100; 68 targets all-time.
✓
get_grades_consensus / get_stock_grades 25 Buy / 11 Hold / 1 Sell; 12 recent actions all 'maintain'.
✓
get_ratings_snapshot FMP B (3/5); P/E & P/B sub-scores dragged by the charge-distorted reported figure — treated as cross-reference only.
⚠
get_analyst_estimates FY2027–30 annual estimates present (2027 EPS $9.64 corroborated clean EPS); FY2026 line not returned — clean run-rate taken from operating decomposition + prior calibration.
✓
get_economic_series (DGS10) 10-Y Treasury 4.56% (2026-07-08) — the risk-free in the warranted-multiple anchor.
✗
get_earnings_calendar Returned empty for MRK — web-fallback confirmed Q2 2026 earnings 2026-08-04 (Merck IR + StockTitan).
✓
get_economic_calendar / get_polygon_news + web search Macro calendar, sentiment-scored news, and Keytruda/IRA/pipeline facts (Fierce Pharma, CNBC, Merck IR).
Impact on scores: Two gaps, both handled with no material score impact. (1) get_earnings_calendar failed — the next-earnings date (4 Aug) was verified by web fallback, so scheduling is unaffected. (2) get_analyst_estimates did not return an FY2026 line — the clean run-rate EPS (~$9.0) was derived from the operating-earnings decomposition and cross-checked against FY2027 consensus ($9.64) and the prior calibration, so the Valuation anchor stands. Overall confidence is set by the min pillar (Timing, 62%), reflecting price being extended vs the ideal entry zone rather than any data hole.
DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.